Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios

Table 2 Estimates from the pooled adjusted Cox regression

Effect	Group	(Non-ICU Subgroup)	HR	95% CI	p
Age			1.83	1.43, 2.35	< 0.001
Female			0.78	0.69, 0.87	< 0.001
log(BMI)			0.91	0.87, 0.94	< 0.001
MAP			0.88	0.84, 0.93	< 0.001
log(eGFR)			0.89	0.84, 0.95	< 0.001
COV50	ICU		1.2	1.17, 1.24	< 0.001
	Non-ICU		1.61	1.47, 1.76	< 0.001
		CVD	1.51	1.36, 1.68	< 0.001
		Diabetes	1.24	1.23, 1.25	< 0.001
		Population	1.68	1.31, 2.15	< 0.001
		CKD	1.82	1.70, 1.94	< 0.001
		Other	1.75	1.45, 2.11	< 0.001

All regressors besides Female and COV50 are were normalized to mean 0 and sd 1
n = 9193; N events = 1205;
statistic.wald = 7,096; p = < 0.001;
c-index = 0.618; c-index SE = 0.013;
Log-likelihood = − 5959
BMI body mass index, CI Confidence Interval, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, HR Hazard Ratio, ICU intensive care unit; MAP mean arterial pressure

ISSN: 1479-5876